Evidence map›Paper›PMID 28742119›Full record

ArticlePloS one2017

DoEstRare: A statistical test to identify local enrichments in rare genomic variants associated with disease.

Elodie Persyn, Matilde Karakachoff, Solena Le Scouarnec, Camille Le Clézio, Dominique Campion, French Exome Consortium, Jean-Jacques Schott, Richard Redon, Lise Bellanger, Christian Dina

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Elodie PersynINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.ORCID http://orcid.org/0000-0001-9104-1972
Matilde KarakachoffINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
Solena Le ScouarnecINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
Camille Le ClézioInserm U1079, Rouen University, Normandy Center for Genomic Medicine and Personalized Medicine, Normandy University, Rouen, France.
Dominique CampionInserm U1079, Rouen University, Normandy Center for Genomic Medicine and Personalized Medicine, Normandy University, Rouen, France.
French Exome ConsortiumINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.ORCID http://orcid.org/0000-0003-4117-2813
Jean-Jacques SchottINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
Richard RedonINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
Lise BellangerLaboratoire de Mathématiques Jean Leray, UMR CNRS 6629, Nantes, France.
Christian DinaINSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France.
Centre National de la Recherche Scientifique · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation sequencing technologies made it possible to assay the effect of rare variants on complex diseases. As an extension of the "common disease-common variant" paradigm, rare variant studies are necessary to get a more complete insight into the genetic architecture of human traits. Association studies of these rare variations show new challenges in terms of statistical analysis. Due to their low frequency, rare variants must be tested by groups. This approach is then hindered by the fact that an unknown proportion of the variants could be neutral. The risk level of a rare variation may be determined by its impact but also by its position in the protein sequence. More generally, the molecular mechanisms underlying the disease architecture may involve specific protein domains or inter-genic regulatory regions. While a large variety of methods are optimizing functionality weights for each single marker, few evaluate variant position differences between cases and controls. Here, we propose a test called DoEstRare, which aims to simultaneously detect clusters of disease risk variants and global allele frequency differences in genomic regions. This test estimates, for cases and controls, variant position densities in the genetic region by a kernel method, weighted by a function of allele frequencies. We compared DoEstRare with previously published strategies through simulation studies as well as re-analysis of real datasets. Based on simulation under various scenarios, DoEstRare was the sole to consistently show highest performance, in terms of type I error and power both when variants were clustered or not. DoEstRare was also applied to Brugada syndrome and early-onset Alzheimer's disease data and provided complementary results to other existing tests. DoEstRare, by integrating variant position information, gives new opportunities to explain disease susceptibility. DoEstRare is implemented in a user-friendly R package.

Indexed as

Genetic VariationAlzheimer DiseaseBiostatisticsBrugada SyndromeCase-Control StudiesComputer SimulationGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyGenomicsHigh-Throughput Nucleotide SequencingHumansModels, Genetic

Identifiers

PMID28742119
PMCPMC5524342
OpenAlexW2943194581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.